Neuropathology provides clues to the pathophysiology

Molecular Genetics and Metabolism
82, 192-207
DOI: 10.1016/j.ymgme.2004.04.011

Citation Report

#	Article	IF	Citations
1	Parkinsonism among Gaucher disease carriers. Journal of Medical Genetics, 2004, 41, 937-940.	1.5	320
2	Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews. New England Journal of Medicine, 2004, 351, 1972-1977.	13.9	559
3	New Genetic Insights into Parkinson's Disease. New England Journal of Medicine, 2004, 351, 1937-1940.	13.9	42
4	Gaucher disease: complexity in a â€œsimpleâ€•disorder. Molecular Genetics and Metabolism, 2004, 83, 6-15.	0.5	350
5	Computerized cognitive testing in patients with type I Gaucher disease: Effects of enzyme replacement and substrate reduction. Genetics in Medicine, 2005, 7, 124-130.	1.1	34
6	Gaucher disease: pathological mechanisms and modern management. British Journal of Haematology, 2005, 129, 178-188.	1.2	240
7	Neurological Manifestations in Lysosomal Storage Disorders - From Pathology to First Therapeutic Possibilities. Neuropediatrics, 2005, 36, 285-289.	0.3	31
8	PERINATAL LETHAL GAUCHER DISEASE: A DISTINCT PHENOTYPE ALONG THE NEURONOPATHIC CONTINUUM. Fetal and Pediatric Pathology, 2005, 24, 205-222.	0.4	44
9	Mutations in the glucocerebrosidase gene and Parkinson disease: Phenotypeâ€“genotype correlation:. Neurology, 2005, 65, 1460-1461.	1.5	74
10	Gaucher disease and parkinsonism. Molecular Genetics and Metabolism, 2005, 84, 302-304.	0.5	75
11	A Chaperone-Mediated Approach to??Enzyme Enhancement as a Therapeutic Option for the Lysosomal??Storage Disorders. Drugs in R and D, 2006, 7, 339-348.	1.1	19
12	Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology, 2006, 67, 908-910.	1.5	204
14	Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells, Molecules, and Diseases, 2006, 36, 426-428.	0.6	118
15	Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism. Neuroscience Letters, 2006, 404, 163-165.	1.0	14
16	High frequency of mutation G377S in Brazilian type 3 Gaucher disease patients. Brazilian Journal of Medical and Biological Research, 2006, 39, 1171-1179.	0.7	101
17	Heterozygosity for a Mendelian disorder as a risk factor for complex disease. Clinical Genetics, 2006, 70, 275-282.	1.0	53
18	Inborn errors of metabolism: the flux from Mendelian to complex diseases. Nature Reviews Genetics, 2006, 7, 449-459.	7.7	113
19	Glucosylceramide transfer from lysosomesâ€”the missing link in molecular pathology of glucosylceramidase deficiency: A hypothesis based on existing data. Journal of Inherited Metabolic Disease, 2006, 29, 707-715.	1.7	39

#	Article	IF	Citations
20	Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela. Movement Disorders, 2006, 21, 282-283.	2.2	64
21	Self-stimulatory behavior associated with deep brain stimulation in Parkinson's disease. Movement Disorders, 2006, 21, 283-285.	2.2	34
22	Gaucher Disease and the Synucleinopathies. Journal of Biomedicine and Biotechnology, 2006, 2006, 1-6.	3.0	45
23	Characterization of neuronopathic Gaucher disease among ethnic Poles. Genetics in Medicine, 2006, 8, 8-15.	1.1	30
24	Lewy bodies. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1661-1668.	3.3	401
25	Downregulation of neurotrophic factors in the brain of a mouse model of Gaucher disease: implications for neuronal loss in Gaucher disease. Experimental and Molecular Medicine, 2006, 38, 348-356.	3.2	17
26	Murine models of acute neuronopathic Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 17483-17488.	3.3	160
27	Chapter 8 Î±-Synuclein and Synucleinopathies. Blue Books of Neurology, 2007, 30, 186-215.	0.1	4
28	Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease. Molecular Genetics and Metabolism, 2007, 91, 195-200.	0.5	111
29	Neurological and brain MRS findings in patients with Gaucher disease type 1. Molecular Genetics and Metabolism, 2007, 91, 390-395.	0.5	16
30	GM1 Specifically Interacts with Î±-Synuclein and Inhibits Fibrillation. Biochemistry, 2007, 46, 1868-1877.	1.2	239
32	Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier. Journal of the Neurological Sciences, 2007, 252, 181-184.	0.3	33
33	Altered intracellular redox status in Gaucher disease fibroblasts and impairment of adaptive response against oxidative stress. Journal of Cellular Physiology, 2007, 212, 223-235.	2.0	42
34	Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Movement Disorders, 2007, 22, 1481-1484.	2.2	103
35	Structure of acid Î²-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nature Chemical Biology, 2007, 3, 101-107.	3.9	213
36	Movement and mood disorder in two brothers with Gaucher disease. Clinical Genetics, 2007, 72, 357-361.	1.0	10
37	Neurologic Improvement in a Type 3 Gaucher Disease Patient Treated with Imiglucerase/Miglustat Combination. Epilepsia, 2007, 48, 1406-1408.	2.6	59
38	Substrate reduction therapy for lysosomal storage diseases. Acta Paediatrica, International Journal of Paediatrics, 2005, 94, 69-75.	0.7	25

#	Article	IF	Citations
39	Neuronal and glial accumulation of Î±- and Î²-synucleins in human lipidoses. Acta Neuropathologica, 2007, 114, 481-489.	3.9	79
40	â€˜Nonâ€neuronopathicâ€™ Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. Journal of Inherited Metabolic Disease, 2008, 31, 337-349.	1.7	79
41	Movement disorders and inborn errors of metabolism in adults: A diagnostic approach. Journal of Inherited Metabolic Disease, 2008, 31, 308-318.	1.7	79
42	Cognitive Outcome in Treated Patients with Chronic Neuronopathic Gaucher Disease. Journal of Pediatrics, 2008, 153, 89-94.e4.	0.9	39
43	Chapter 6 Molecular and Cellular Biology of Synucleins. International Review of Cell and Molecular Biology, 2008, 270, 225-317.	1.6	90
44	Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity. Molecular Brain, 2008, 1, 17.	1.3	212
45	Treating patients with Gaucher disease and parkinsonism: Misrepresentation in a title. Parkinsonism and Related Disorders, 2008, 14, 81-82.	1.1	3
46	Association between Parkinson's disease and glucocerebrosidase mutations in Brazil. Parkinsonism and Related Disorders, 2008, 14, 58-62.	1.1	62
47	Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid Î²-glucosidase residual activity levels. Molecular Genetics and Metabolism, 2008, 94, 190-203.	0.5	35
48	Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet, The, 2008, 372, 1263-1271.	6.3	518
49	Gaucher and Parkinson diseases. Neurology, 2008, 70, 2272-2273.	1.5	24
51	Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain, 2009, 132, 1783-1794.	3.7	612
52	No evidence for activation of the unfolded protein response in neuronopathic models of Gaucher disease. Human Molecular Genetics, 2009, 18, 1482-1488.	1.4	52
53	Recommendations on Diagnosis, Treatment, and Monitoring for Gaucher Disease. Journal of Pediatrics, 2009, 155, S10-S18.	0.9	45
54	Treating lysosomal storage disorders: Current practice and future prospects. Biochimica Et Biophysica Acta - Molecular Cell Research, 2009, 1793, 737-745.	1.9	76
55	The association between mutations in the lysosomal protein glucocerebrosidase and parkinsonism. Movement Disorders, 2009, 24, 1571-1578.	2.2	71
56	Apparent diffusion coefficient vale of the brain in patients with Gaucherâ€™s disease type II and type III. Neuroradiology, 2009, 51, 773-779.	1.1	29
57	The genetics of Parkinson's syndromes: a critical review. Current Opinion in Genetics and Development, 2009, 19, 254-265.	1.5	195

#	Article	IF	Citations
58	Parkinson's disease and the heterozygous state for glucocerebrosidase mutations among Brazilians. Parkinsonism and Related Disorders, 2009, 15, 76-78.	1.1	15
59	Complete screening for glucocerebrosidase mutations in Parkinson disease patients from Greece. Neuroscience Letters, 2009, 452, 87-89.	1.0	94
60	Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: A biological link between Gaucher disease and parkinsonism. NeuroToxicology, 2009, 30, 1127-1132.	1.4	164
62	Parkinson's disease: from monogenic forms to genetic susceptibility factors. Human Molecular Genetics, 2009, 18, R48-R59.	1.4	816
64	Parkinson's disease. Lancet, The, 2009, 373, 2055-2066.	6.3	1,835
65	Etiology and Pathogenesis of Parkinson Disease. Neurologic Clinics, 2009, 27, 583-603.	0.8	105
66	Glucocerebrosidase as a genetic modifier influencing susceptibility and phenotype of Parkinsonâ€™s disease. Future Neurology, 2010, 5, 189-193.	0.9	0
67	The Genetics of Parkinson Disease. Journal of Geriatric Psychiatry and Neurology, 2010, 23, 228-242.	1.2	259
68	Î±-Synuclein: Membrane Interactions and Toxicity in Parkinson's Disease. Annual Review of Cell and Developmental Biology, 2010, 26, 211-233.	4.0	467
69	Glucocerebrosidase is present in Î±-synuclein inclusions in Lewy body disorders. Acta Neuropathologica, 2010, 120, 641-649.	3.9	169
70	Neuropathic Gaucher disease. Wiener Medizinische Wochenschrift, 2010, 160, 605-608.	0.5	32
71	The Role of Glucocerebrosidase Mutations in Parkinson Disease and Lewy Body Disorders. Current Neurology and Neuroscience Reports, 2010, 10, 190-198.	2.0	131
72	The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG). Journal of Inherited Metabolic Disease, 2010, 33, 331-338.	1.7	63
73	Aberrant Ca2+ handling in lysosomal storage disorders. Cell Calcium, 2010, 47, 103-111.	1.1	46
74	Transient amantadine-induced musical hallucinations in a patient with Parkinson's disease. Movement Disorders, 2010, 25, 1505-1506.	2.2	12
75	Gaucher disease ascertained through a Parkinson's center: Imaging and clinical characterization. Movement Disorders, 2010, 25, 1364-1372.	2.2	77
76	Atypical parkinsonism with apraxia and supranuclear gaze abnormalities in type 1 Gaucher disease. Expanding the spectrum: Case report and literature review. Movement Disorders, 2010, 25, 1506-1509.	2.2	21
77	Rare and serious cardiac side effects during ropinirole titration. Movement Disorders, 2010, 25, 1509-1510.	2.2	8

#	Article	IF	Citations
78	Valproateâ€induced reversible hemichorea. Movement Disorders, 2010, 25, 1511-1512.	2.2	15
79	Facial tic associated with lamotrigine in adults. Movement Disorders, 2010, 25, 1512-1513.	2.2	10
80	Primary progressive freezing gait in a patient with COâ€induced parkinsonism. Movement Disorders, 2010, 25, 1513-1515.	2.2	14
81	Multiple system atrophy and colon inertia. Movement Disorders, 2010, 25, 1515-1516.	2.2	0
82	Multipleâ€system atrophy presenting with low rectal compliance and bowel pain. Movement Disorders, 2010, 25, 1516-1518.	2.2	3
83	Changes in apraxia after deep brain stimulation of the nucleus basalis Meynert in a patient with Parkinson dementia syndrome. Movement Disorders, 2010, 25, 1519-1520.	2.2	43
84	Congenital mirror movements in Parkinson's disease: Clinical and neurophysiological observations. Movement Disorders, 2010, 25, 1520-1523.	2.2	6
85	Parkinsonism and cognitive decline in a fragile X mosaic male. Movement Disorders, 2010, 25, 1523-1524.	2.2	12
86	Olfactory dysfunction in Japanese patients with idiopathic REM sleep behavior disorder: Comparison of data using the university of Pennsylvania smell identification test and odor stick identification test for Japanese. Movement Disorders, 2010, 25, 1524-1526.	2.2	11
87	Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease. Molecular Neurodegeneration, 2010, 5, 14.	4.4	49
88	Glucocerebrosidase Gene Mutations and Parkinsonism. , 2010, , 555-557.		0
89	Altered expression and distribution of cathepsins in neuronopathic forms of Gaucher disease and in other sphingolipidoses. Human Molecular Genetics, 2010, 19, 3583-3590.	1.4	76
90	Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits. Human Molecular Genetics, 2010, 19, 1088-1097.	1.4	113
91	Multi-system disorders of glycosphingolipid and ganglioside metabolism. Journal of Lipid Research, 2010, 51, 1643-1675.	2.0	133
92	Gaucher disease and parkinsonism, a molecular link theory. Molecular Genetics and Metabolism, 2010, 101, 307-310.	0.5	18
93	Intracerebroventricular delivery of glucocerebrosidase reduces substrates and increases lifespan in a mouse model of neuronopathic Gaucher disease. Experimental Neurology, 2010, 225, 436-444.	2.0	28
94	Emerging parkinsonian phenotypes. Revue Neurologique, 2010, 166, 834-840.	0.6	3
95	Genetic basis of Parkinson disease. Neurosurgical Focus, 2010, 28, E7.	1.0	35

#	Article	IF	Citations
96	Animal models for Gaucher disease research. DMM Disease Models and Mechanisms, 2011, 4, 746-752.	1.2	80
97	Gaucher Disease Glucocerebrosidase and Î±-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies. Cell, 2011, 146, 37-52.	13.5	1,097
98	Exploring the link between glucocerebrosidase mutations and parkinsonism. Trends in Molecular Medicine, 2011, 17, 485-493.	3.5	146
99	Accumulation and distribution of Î±-synuclein and ubiquitin in the CNS of Gaucher disease mouse models. Molecular Genetics and Metabolism, 2011, 102, 436-447.	0.5	130
100	Glucocerebrosidase mutations do not cause increased Lewy body pathology in Parkinson's disease. Molecular Genetics and Metabolism, 2011, 103, 410-412.	0.5	40
101	Aggregation of Î±-synuclein in brain samples from subjects with glucocerebrosidase mutations. Molecular Genetics and Metabolism, 2011, 104, 185-188.	0.5	67
102	Î²-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease. Molecular Genetics and Metabolism, 2011, 104, 149-152.	0.5	47
103	Glucocerebrosidase mutations in diffuse Lewy body disease. Parkinsonism and Related Disorders, 2011, 17, 55-57.	1.1	43
105	Neuronopathic Forms in Subjects with Mutations in GBA Gene. , 0, , .		1
106	Bridging Molecular Genetics and Biomarkers in Lewy Body and Related Disorders. International Journal of Alzheimer's Disease, 2011, 2011, 1-18.	1.1	7
108	Sialidosis and Gaucher disease. , 0, , 164-168.		0
109	What Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease. Physiological Reviews, 2011, 91, 1161-1218.	13.1	515
110	Brain white matter abnormalities in paediatric Gaucher Type I and Type III using diffusion tensor imaging. Journal of Inherited Metabolic Disease, 2011, 34, 549-553.	1.7	24
111	Alzheimerâ€™s disease is not â€œbrain agingâ€: neuropathological, genetic, and epidemiological human studies. Acta Neuropathologica, 2011, 121, 571-587.	3.9	273
112	Decades of delayed diagnosis in 4 levodopaâ€responsive youngâ€onset monogenetic parkinsonism patients. Movement Disorders, 2011, 26, 1337-1340.	2.2	4
113	Thalamic neuronal and EMG activity in psychogenic dystonia compared with organic dystonia. Movement Disorders, 2011, 26, 1348-1352.	2.2	18
114	Osteopontin polymorphic susceptibility factor for Parkinson's disease among patients with Gaucher disease. Movement Disorders, 2011, 26, 1341-1343.	2.2	6
115	Pupillary unrest correlates with arousal symptoms and motor signs in Parkinson disease. Movement Disorders, 2011, 26, 1344-1347.	2.2	17

#	Article	IF	Citations
116	Milestones in PD genetics. Movement Disorders, 2011, 26, 1042-1048.	2.2	147
117	Lysosomal storage disorders and Parkinson's disease: Gaucher disease and beyond. Movement Disorders, 2011, 26, 1593-1604.	2.2	141
118	Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease. Human Molecular Genetics, 2011, 20, 1375-1386.	1.4	93
119	A Lysosomal Lair for a Pathogenic Protein Pair. Science Translational Medicine, 2011, 3, 91ps28.	5.8	11
120	CNS expression of glucocerebrosidase corrects Î±-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12101-12106.	3.3	282
121	Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease. Brain, 2012, 135, 1724-1735.	3.7	132
122	The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow. Brain, 2012, 135, 2440-2448.	3.7	81
123	Glucocerebrosidase Mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease. Journal of Neurochemistry, 2012, 123, 298-309.	2.1	58
124	The link between the GBA gene and parkinsonism. Lancet Neurology, The, 2012, 11, 986-998.	4.9	475
125	The cognitive profile of type 1 Gaucher disease patients. Journal of Inherited Metabolic Disease, 2012, 35, 1093-1099.	1.7	17
126	Mutant <i>GBA1</i> Expression and Synucleinopathy Risk: First Insights from Cellular and Mouse Models. Neurodegenerative Diseases, 2012, 10, 195-202.	0.8	26
127	The role of saposin C in Gaucher disease. Molecular Genetics and Metabolism, 2012, 106, 257-263.	0.5	108
128	GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology, 2012, 79, 1944-1950.	1.5	138
129	Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Annals of Neurology, 2012, 72, 455-463.	2.8	473
130	Lysosomeâ€dependent pathways as a unifying theme in Parkinson's disease. Movement Disorders, 2012, 27, 1364-1369.	2.2	103
131	Glucocerebrosidase Involvement in Parkinson Disease and Other Synucleinopathies. Frontiers in Neurology, 2012, 3, 65.	1.1	15
132	Animal Models of Parkinsonâ€™s Disease Induced by Toxins and Genetic Manipulation. , 2012, , .		0
133	The neuropathology of genetic Parkinson's disease. Movement Disorders, 2012, 27, 831-842.	2.2	229

#	Article	IF	Citations
134	Cerebrospinal fluid fatty acids in glucocerebrosidaseâ€associated Parkinson's disease. Movement Disorders, 2012, 27, 288-293.	2.2	19
135	Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson's disease. Movement Disorders, 2012, 27, 400-405.	2.2	56
136	The Association Between ÃŸ-Glucocerebrosidase Mutations and Parkinsonism. Current Neurology and Neuroscience Reports, 2013, 13, 368.	2.0	32
137	Sphingolipids in Disease. Handbook of Experimental Pharmacology, 2013, , .	0.9	7
138	Î±-Synuclein and Neuronal Cell Death. Molecular Neurobiology, 2013, 47, 466-483.	1.9	97
139	Proton MR Spectroscopy of the brain in children with neuronopathic Gaucherâ€™s disease. European Radiology, 2013, 23, 3005-3011.	2.3	24
140	Increased incidence of Parkinsonism among Chinese with Î²-glucosidase mutation in central Taiwan.		

#	Article	IF	Citations
152	â€œAtypicalâ€•atypical parkinsonism: New genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophyâ€”A diagnostic guide. Movement Disorders, 2013, 28, 1184-1199.	2.2	167
153	Parkinsonâ€™s disease in patients and obligate carriers of Gaucher disease. Parkinsonism and Related Disorders, 2013, 19, 129-131.	1.1	13
154	Gaucher disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 113, 1709-1715.	1.0	22
158	Emerging insights into the mechanistic link between Î±-synuclein and glucocerebrosidase in Parkinson's disease. Biochemical Society Transactions, 2013, 41, 1509-1512.	1.6	14
159	Hypercoagulability, Parkinsonism, and Gaucher Disease. Seminars in Thrombosis and Hemostasis, 2013, 39, 928-934.	1.5	10
160	The pallidopyramidal syndromes. Current Opinion in Neurology, 2013, 26, 381-394.	1.8	25
161	Neuronopathic Gaucher's disease: induced pluripotent stem cells for disease modelling and testing chaperone activity of small compounds. Human Molecular Genetics, 2013, 22, 633-645.	1.4	75
162	Glucocerebrosidase, a new player changing the old rules in Lewy body diseases. Biological Chemistry, 2013, 394, 807-818.	1.2	14
164	The genetics of behavior and cognition in Parkinsonâ€™s disease. , 0, , 25-39.		0
165	More Than Hypomyelination in Pol-III Disorder. Journal of Neuropathology and Experimental Neurology, 2013, 72, 67-75.	0.9	27
166	A Multicenter Study of Glucocerebrosidase Mutations in Dementia With Lewy Bodies. JAMA Neurology, 2013, 70, 727.	4.5	374
167	Loss of Î²-Glucocerebrosidase Activity Does Not Affect Alpha-Synuclein Levels or Lysosomal Function in Neuronal Cells. PLoS ONE, 2013, 8, e60674.	1.1	47
168	Gaucher Disease: Transcriptome Analyses Using Microarray or mRNA Sequencing in a Gba1 Mutant Mouse Model Treated with Velaglucerase alfa or Imiglucerase. PLoS ONE, 2013, 8, e74912.	1.1	18
169	Ocular Abnormality of Korean Patients with Molecular Genetically Confirmed Gaucher Disease. Journal of Korean Ophthalmological Society, 2013, 54, 131.	0.0	1
170	A Case of Acquired Ocular Motor Apraxia Accompanied with Esotropia due to Multiple Brain Infarcts. Journal of Korean Ophthalmological Society, 2014, 55, 1396.	0.0	0
171	The genetics of Parkinson’s disease: review of current and emerging candidates. Journal of Parkinsonism and Restless Legs Syndrome, 2014, , 63.	0.8	1
172	Lysosomes and Nanotherapeutics: Diseases, Treatments, and Side Effects. Frontiers in Nanobiomedical Research, 2014, , 261-305.	0.1	2
173	Towards Small Molecules as Therapies for Alzheimerâ€™s Disease and Other Neurodegenerative Disorders. , 2014, , 199-290.		2

#	Article	IF	Citations
174	Visual short-term memory deficits associated with GBA mutation and Parkinsonâ€™s disease. Brain, 2014, 137, 2303-2311.	3.7	77
175	Scientific correspondence. Neuropathology and Applied Neurobiology, 2014, 40, 946-950.	1.8	2
176	Peripheral Autonomic Nervous System Involvement in Gaucher-Related Parkinsonism. Journal of Parkinson's Disease, 2014, 4, 29-32.	1.5	12
177	Quality control gone wrong: mitochondria, lysosomal storage disorders and neurodegeneration. British Journal of Pharmacology, 2014, 171, 1958-1972.	2.7	71
178	Niemannâ€‹<scp>P</scp>ick disease type <scp>C</scp>1 predominantly involving the frontotemporal region, with cortical and brainstem <scp>L</scp>ewy bodies: An autopsy case. Neuropathology, 2014, 34, 49-57.	0.7	35
179	Development of targeted therapies for Parkinson's disease and related synucleinopathies. Journal of Lipid Research, 2014, 55, 1996-2003.	2.0	17
180	Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration. Human Molecular Genetics, 2014, 23, 843-854.	1.4	123
181	Human stem cell models of neurodegeneration: a novel approach to study mechanisms of disease development. Acta Neuropathologica, 2014, 127, 151-173.	3.9	44
182	Parkinson's disease in a dish â€“ Using stem cells as a molecular tool. Neuropharmacology, 2014, 76, 88-96.	2.0	71
183	Niemannâ€“Pick's and Gaucher's diseases. Parkinsonism and Related Disorders, 2014, 20, S143-S146.	1.1	14
184	Neuroinflammation and Î±-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction. Molecular Genetics and Metabolism, 2014, 111, 152-162.	0.5	94
185	Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation. Brain, 2014, 137, 3235-3247.	3.7	88
186	LIMP-2 expression is critical for Î²-glucocerebrosidase activity and Î±-synuclein clearance. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15573-15578.	3.3	109
187	RIPK3 as a potential therapeutic target for Gaucher's disease. Nature Medicine, 2014, 20, 204-208.	15.2	147
188	Î±-Synuclein rs356219 polymorphisms in patients with Gaucher disease and Parkinson disease. Neuroscience Letters, 2014, 580, 104-107.	1.0	2
189	Cognitive and Antipsychotic Medication Use in Monoallelic GBA-Related Parkinson Disease. JIMD Reports, 2014, 16, 31-38.	0.7	12
190	Glycobiology of the Nervous System. Advances in Neurobiology, 2014, , .	1.3	9
191	The significance of GBA for Parkinson's disease. Journal of Inherited Metabolic Disease, 2014, 37, 643-648.	1.7	36

#	Article	IF	Citations
192	Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Human Molecular Genetics, 2014, 23, 3943-3957.	1.4	79
193	Mesenchymal stem cells as cellular vectors for pediatric neurological disorders. Brain Research, 2014, 1573, 92-107.	1.1	17
194	79â€Year Old Man with Parkinsonism and Acute Spinal Cord Compression. Brain Pathology, 2014, 24, 101-102.	2.1	0
195	Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry. American Journal of Hematology, 2015, 90, S12-8.	2.0	93
196	Color Discrimination in Patients with Gaucher Disease and Parkinson Disease. Journal of Parkinson's Disease, 2015, 5, 525-531.	1.5	2
197	Gaucher Disease. , 2015, , 301-311.		0
198	Visualization of Active Glucocerebrosidase in Rodent Brain with High Spatial Resolution following In Situ Labeling with Fluorescent Activity Based Probes. PLoS ONE, 2015, 10, e0138107.	1.1	28
199	Gaucher Disease and Dementia. , 2015, , 67-75.		0
200	Gaucher-related synucleinopathies: The examination of sporadic neurodegeneration from a rare (disease) angle. Progress in Neurobiology, 2015, 125, 47-62.	2.8	63
201	Lipidomic profiling of plasma and urine from patients with Gaucher disease during enzyme replacement therapy by nanoflow liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography A, 2015, 1381, 132-139.	1.8	35
202	Fluorescence-Quenched Substrates for Live Cell Imaging of Human Glucocerebrosidase Activity. Journal of the American Chemical Society, 2015, 137, 1181-1189.	6.6	59
203	The endosomal pathway in Parkinson's disease. Molecular and Cellular Neurosciences, 2015, 66, 21-28.	1.0	71
204	Innate immune responses in the brain of sphingolipid lysosomal storage diseases. Biological Chemistry, 2015, 396, 659-667.	1.2	23
205	Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells. Human Molecular Genetics, 2015, 24, 5775-5788.	1.4	102
206	Viable Neuronopathic Gaucher Disease Model in Medaka (Oryzias latipes) Displays Axonal Accumulation of Alpha-Synuclein. PLoS Genetics, 2015, 11, e1005065.	1.5	60
207	Sustained Systemic Glucocerebrosidase Inhibition Induces Brain Î±-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice. Antioxidants and Redox Signaling, 2015, 23, 550-564.	2.5	118
208	Gaucher-Associated Parkinsonism. Cellular and Molecular Neurobiology, 2015, 35, 755-761.	1.7	22
209	Glucocerebrosidase and Parkinson disease: Recent advances. Molecular and Cellular Neurosciences, 2015, 66, 37-42.	1.0	184

#	Article	IF	Citations
210	Understanding and managing parkinsonism in patients with glucocerebrosidase mutations. Expert Opinion on Orphan Drugs, 2015, 3, 549-562.	0.5	1
211	CNS, lung, and lymph node involvement in Gaucher disease type 3 after 11years of therapy: Clinical, histopathologic, and biochemical findings. Molecular Genetics and Metabolism, 2015, 114, 233-241.	0.5	54
212	Neuronopathic Gaucher disease: dysregulated mRNAs and miRNAs in brain pathogenesis and effects of pharmacologic chaperone treatment in a mouse model. Human Molecular Genetics, 2015, 24, ddv404.	1.4	36
213	GBA deficiency promotes SNCA/Î±-synuclein accumulation through autophagic inhibition by inactivated PPP2A. Autophagy, 2015, 11, 1803-1820.	4.3	106
214	Imaging in Glucocerebrosidase-Associated Parkinsonism: Current Status and Implications for Pathophysiology. Neurodegenerative Diseases, 2015, 15, 271-280.	0.8	3
215	Genotypeâ€“Phenotype Correlations in Parkinson Disease. , 2015, , 259-285.		1
216	The emergence of Parkinson disease among patients with Gaucher disease. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 249-259.	2.2	12
217	Genetic Convergence of Parkinsonâ€™s Disease and Lysosomal Storage Disorders. Molecular Neurobiology, 2015, 51, 1554-1568.	1.9	22
218	Induction of the type I interferon response in neurological forms of Gaucher disease. Journal of Neuroinflammation, 2016, 13, 104.	3.1	53
219	Progression of Behavioral and CNS Deficits in a Viable Murine Model of Chronic Neuronopathic Gaucher Disease. PLoS ONE, 2016, 11, e0162367.	1.1	16
220	The Genetic Basis of Cognitive Impairment and Dementia in Parkinsonâ€™s Disease. Frontiers in Psychiatry, 2016, 7, 89.	1.3	46
221	Delineating pathological pathways in a chemically induced mouse model of Gaucher disease. Journal of Pathology, 2016, 239, 496-509.	2.1	54
222	Glucocerebrosidase in Parkinson's disease: Insights into pathogenesis and prospects for treatment. Movement Disorders, 2016, 31, 830-835.	2.2	32
223	Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. Human Molecular Genetics, 2016, 25, 3432-3445.	1.4	171
224	Clinical studies of GBA1-associated parkinsonism: progress and challenges. Neurodegenerative Disease Management, 2016, 6, 1-4.	1.2	4
225	Long-term follow-up and sudden unexpected death in Gaucher disease type 3 in Egypt. Neurology: Genetics, 2016, 2, e55.	0.9	17
226	High Frequency of GBA Gene Mutations in Dementia With Lewy Bodies Among Ashkenazi Jews. JAMA Neurology, 2016, 73, 1448.	4.5	48
227	Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice. Human Molecular Genetics, 2016, 25, ddw322.	1.4	30

#	Article	IF	Citations
228	Parkinson Disease and Dementia. Journal of Geriatric Psychiatry and Neurology, 2016, 29, 261-270.	1.2	52
229	The lysosomal storage disease continuum with ageing-related neurodegenerative disease. Ageing Research Reviews, 2016, 32, 104-121.	5.0	34
230	Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study. Annals of Clinical and Translational Neurology, 2016, 3, 200-215.	1.7	150
231	Parkinson's disease: acidâ€glucocerebrosidase activity and alphaâ€synuclein clearance. Journal of Neurochemistry, 2016, 139, 198-215.	2.1	59
232	Glycobiology of Human Milk in Health and Disease. , 2016, , 233-250.		0
233	Survival and dementia in <scp>GBA</scp>â€associated Parkinson's disease: <scp>T</scp>he mutation matters. Annals of Neurology, 2016, 80, 662-673.	2.8	312
234	Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease. Movement Disorders, 2016, 31, 1610-1618.	2.2	47
235	Varied autopsy findings in five treated patients with Gaucher disease and parkinsonism include the absence of Gaucher cells. Molecular Genetics and Metabolism, 2016, 118, 55-59.	0.5	4
236	Astrocytes and lysosomal storage diseases. Neuroscience, 2016, 323, 195-206.	1.1	31
237	Autophagy, lipophagy and lysosomal lipid storage disorders. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 269-284.	1.2	189
238	Glucocerebrosidase and parkinsonism: lessons to learn. Journal of Neurology, 2016, 263, 1033-1044.	1.8	6
239	Î±-Synucleinâ€“induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1931-1936.	3.3	292
240	Membrane lipids as therapeutic targets for Parkinsonâ€™s disease: a possible link between Lewy pathology and membrane lipids. Expert Opinion on Therapeutic Targets, 2016, 20, 1301-1310.	1.5	9
241	Mitochondrial dysfunction associated with glucocerebrosidase deficiency. Neurobiology of Disease, 2016, 90, 43-50.	2.1	79
242	Altered lysosome distribution is an early neuropathological event in neurological forms of Gaucher disease. FEBS Letters, 2017, 591, 774-783.	1.3	20
244	Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration. Human Molecular Genetics, 2017, 26, 2603-2615.	1.4	37
245	Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinsonâ€™s disease. Expert Review of Molecular Diagnostics, 2017, 17, 771-780.	1.5	23
246	Glucosylsphingosine Promotes Î±-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease. Journal of Neuroscience, 2017, 37, 9617-9631.	1.7	180

#	Article	IF	Citations
247	Overview of Inflammation in Neurometabolic Diseases. Seminars in Pediatric Neurology, 2017, 24, 207-213.	1.0	16
248	Altered Differentiation Potential of Gaucherâ€™s Disease iPSC Neuronal Progenitors due to Wnt/Î²-Catenin Downregulation. Stem Cell Reports, 2017, 9, 1853-1867.	2.3	42
249	A Therapeutic Target for Inhibition of Neurodegeneration: Autophagy. Neuroscience and Behavioral Physiology, 2017, 47, 1109-1127.	0.2	5
250	Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature. Movement Disorders, 2017, 32, 1504-1523.	2.2	229
251	Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease. Orphanet Journal of Rare Diseases, 2017, 12, 84.	1.2	23
252	Parkinson disease in Gaucher disease. Journal of Clinical Movement Disorders, 2017, 4, 7.	2.2	9
253	Gaucher disease: Progress and ongoing challenges. Molecular Genetics and Metabolism, 2017, 120, 8-21.	0.5	112
254	The Video Head Impulse Test. Frontiers in Neurology, 2017, 8, 258.	1.1	384
255	The Spectrum of Neurological Manifestations Associated with Gaucher Disease. Diseases (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4	1.0	54
256	Induced Pluripotent Stem Cell Modeling of Gaucherâ€™s Disease: What Have We Learned?. International Journal of Molecular Sciences, 2017, 18, 888.	1.8	11
257	Mitochondria: A Common Target for Genetic Mutations and Environmental Toxicants in Parkinsonâ€™s Disease. Frontiers in Genetics, 2017, 8, 177.	1.1	58
258	Dysregulation of autophagy as a common mechanism in lysosomal storage diseases. Essays in Biochemistry, 2017, 61, 733-749.	2.1	138
259	Synuclein misfolding as a therapeutic target. , 2017, , 21-47.		0
260	Glucocerebrosidase Gene Mutations and Parkinsonismâ˜†. , 2017, , .		0
261	Brain white matter microstructural alterations in children of type I Gaucher disease characterized with diffusion tensor MR imaging. European Journal of Radiology, 2018, 102, 22-29.	1.2	8
262	Alpha-synucleinopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 145, 339-353.	1.0	50
263	Reversible Conformational Conversion of Î±-Synuclein into Toxic Assemblies by Glucosylceramide. Neuron, 2018, 97, 92-107.e10.	3.8	161
264	Pathological role of lipid interaction with Î±-synuclein in Parkinson's disease. Neurochemistry International, 2018, 119, 97-106.	1.9	53

#	Article	IF	Citations
265	Gaucher disease iPSC-derived osteoblasts have developmental and lysosomal defects that impair bone matrix deposition. Human Molecular Genetics, 2018, 27, 811-822.	1.4	30
266	The brain lipidome in neurodegenerative lysosomal storage disorders. Biochemical and Biophysical Research Communications, 2018, 504, 623-628.	1.0	20
267	Molecular mechanisms of Î±-synuclein and GBA1 in Parkinsonâ€™s disease. Cell and Tissue Research, 2018, 373, 51-60.	1.5	77
268	Glucocerebrosidase expression patterns in the non-human primate brain. Brain Structure and Function, 2018, 223, 343-355.	1.2	9
269	Parkinsonâ€™s disease pathogenesis from the viewpoint of small fish models. Journal of Neural Transmission, 2018, 125, 25-33.	1.4	20
270	A Focus on the Beneficial Effects of Alpha Synuclein and a Re-Appraisal of Synucleinopathies. Current Protein and Peptide Science, 2018, 19, 598-611.	0.7	17
272	Lysosomal storage diseases. Nature Reviews Disease Primers, 2018, 4, 27.	18.1	563
273	Corticobasal syndrome in a man with Gaucher disease type 1: Expansion of the understanding of the neurological spectrum. Molecular Genetics and Metabolism Reports, 2018, 17, 69-72.	0.4	4
274	Medaka Fish Model of Parkinsonâ€™s Disease. , 2018, , 235-249.		2
275	Fluorescence-Quenched Substrates for Quantitative Live Cell Imaging of Glucocerebrosidase Activity. Methods in Enzymology, 2018, 598, 199-215.	0.4	5
276	Hypermetabolism in the cerebellum and brainstem and cortical hypometabolism are independently associated with cognitive impairment in Parkinsonâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2387-2395.	3.3	23
277	Cognitive impairments in inherited metabolic diseases: Promises and challenges. Cognitive Neuropsychology, 2018, 35, 113-119.	0.4	2
278	Modeling Parkinsonâ€™s Disease in C. elegans. Journal of Parkinson's Disease, 2018, 8, 17-32.	1.5	114
279	Neuroimaging Findings in Lysosomal Disorders. Topics in Magnetic Resonance Imaging, 2018, 27, 259-274.	0.7	8
280	The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress. Neurobiology of Disease, 2018, 120, 1-11.	2.1	85
281	The genetics of dementia with Lewy bodies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 148, 431-440.	1.0	1
282	Absence of infiltrating peripheral myeloid cells in the brains of mouse models of lysosomal storage disorders. Journal of Neurochemistry, 2019, 148, 625-638.	2.1	20
283	The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinsonâ€™s disease. Translational Neurodegeneration, 2019, 8, 23.	3.6	200

#	Article	IF	Citations
284	Arylsulfatase A, a genetic modifier of Parkinsonâ€™s disease, is an Î±-synuclein chaperone. Brain, 2019, 142, 2845-2859.	3.7	44
285	Working Memory in Alzheimerâ€™s Disease and Parkinsonâ€™s Disease. Current Topics in Behavioral Neurosciences, 2019, 41, 325-344.	0.8	29
286	Autophagic- and Lysosomal-Related Biomarkers for Parkinsonâ€™s Disease: Lights and Shadows. Cells, 2019, 8, 1317.	1.8	23
287	The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2019, 20, 5312.	1.8	78
288	Measuring disease activity and patient experience remotely using wearable technology and a mobile phone app: outcomes from a pilot study in Gaucher disease. Orphanet Journal of Rare Diseases, 2019, 14, 212.	1.2	4
289	Insights into GBA Parkinson's disease pathology and therapy with induced pluripotent stem cell model systems. Neurobiology of Disease, 2019, 127, 1-12.	2.1	13
290	Early disease course is unaltered in mucopolysaccharidosis type IIIA (MPS IIIA) mice lacking Î±â€synuclein. Neuropathology and Applied Neurobiology, 2019, 45, 715-731.	1.8	6
291	Glial phagocytic clearance in Parkinsonâ€™s disease. Molecular Neurodegeneration, 2019, 14, 16.	4.4	104
292	Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies. Clinica Chimica Acta, 2019, 495, 13-24.	0.5	18
293	Current and Emerging Pharmacotherapy for Gaucher Disease. Clinical Reviews in Bone and Mineral Metabolism, 2019, 17, 142-151.	1.3	1
294	Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine. Movement Disorders, 2019, 34, 9-21.	2.2	73
295	Neurological effects of glucocerebrosidase gene mutations. European Journal of Neurology, 2019, 26, 388.	1.7	30
296	Sphingolipids in the Pathogenesis of Parkinsonâ€™s Disease and Parkinsonism. Trends in Endocrinology and Metabolism, 2019, 30, 106-117.	3.1	82
297	Altered brain functional network in children with type 1 Gaucher disease: a longitudinal graph theory-based study. Neuroradiology, 2019, 61, 63-70.	1.1	8
298	Dysregulation of the autophagic-lysosomal pathway in Gaucher and Parkinson's disease. Neurobiology of Disease, 2019, 122, 72-82.	2.1	48
299	Neurochemical abnormalities in patients with type 1 Gaucher disease on standard of care therapy. Journal of Inherited Metabolic Disease, 2020, 43, 564-573.	1.7	4
300	Role of endolysosomes and inter-organellar signaling in brain disease. Neurobiology of Disease, 2020, 134, 104670.	2.1	18
301	Pharmacologic properties of high-dose ambroxol in four patients with Gaucher disease and myoclonic epilepsy. Journal of Medical Genetics, 2020, 57, 124-131.	1.5	29

#	Article	IF	Citations
302	A characterization of Gaucher iPS-derived astrocytes: Potential implications for Parkinson's disease. Neurobiology of Disease, 2020, 134, 104647.	2.1	50
303	Systemic AAV9 gene therapy using the synapsin I promoter rescues a mouse model of neuronopathic Gaucher disease but with limited cross-correction potential to astrocytes. Human Molecular Genetics, 2020, 29, 1933-1949.	1.4	24
304	Macular Ganglion Cell Complex and Peripapillary Retinal Nerve Fiber Layer Thinning in Patients with Type-1 Gaucher Disease. International Journal of Molecular Sciences, 2020, 21, 7027.	1.8	2
305	Glycosphingolipids and neuroinflammation in Parkinsonâ€™s disease. Molecular Neurodegeneration, 2020, 15, 59.	4.4	78
306	Arylsulfatase A (ASA) in Parkinsonâ€™s Disease: From Pathogenesis to Biomarker Potential. Brain Sciences, 2020, 10, 713.	1.1	10
307	Trends in Glucocerebrosides Research: A Systematic Review. Frontiers in Physiology, 2020, 11, 558090.	1.3	2
308	Upregulating Î²-hexosaminidase activity in rodents prevents Î±-synuclein lipid associations and protects dopaminergic neurons from Î±-synuclein-mediated neurotoxicity. Acta Neuropathologica Communications, 2020, 8, 127.	2.4	17
309	Microglia and astrocyte dysfunction in parkinson's disease. Neurobiology of Disease, 2020, 144, 105028.	2.1	177
310	Parkinsonism in Patients with Neuronopathic (Type 3) Gaucher Disease: A Case Series. Movement Disorders Clinical Practice, 2020, 7, 834-837.	0.8	5
311	Innate immune response in neuronopathic forms of Gaucher disease confers resistance against viral-induced encephalitis. Acta Neuropathologica Communications, 2020, 8, 144.	2.4	8
312	The Convergence of Alpha-Synuclein, Mitochondrial, and Lysosomal Pathways in Vulnerability of Midbrain Dopaminergic Neurons in Parkinsonâ€™s Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 580634.	1.8	40
313	Elevated Dkk1 Mediates Downregulation of the Canonical Wnt Pathway and Lysosomal Loss in an iPSC Model of Neuronopathic Gaucher Disease. Biomolecules, 2020, 10, 1630.	1.8	8
314	The Emerging Role of the Lysosome in Parkinsonâ€™s Disease. Cells, 2020, 9, 2399.	1.8	63
315	CRISPR/Cas9 Editing for Gaucher Disease Modelling. International Journal of Molecular Sciences, 2020, 21, 3268.	1.8	13
316	Lipids: Key Players That Modulate Î±-Synuclein Toxicity and Neurodegeneration in Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 3301.	1.8	36
317	Finding pathogenic commonalities between Niemann-Pick type C and other lysosomal storage disorders: Opportunities for shared therapeutic interventions. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165875.	1.8	16
318	Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease. CNS Drugs, 2020, 34, 915-923.	2.7	14
319	Lysosomal Ceramide Metabolism Disorders: Implications in Parkinsonâ€™s Disease. Journal of Clinical Medicine, 2020, 9, 594.	1.0	31

#	Article	IF	Citations
320	Fabry Disease With Concomitant Lewy Body Disease. Journal of Neuropathology and Experimental Neurology, 2020, 79, 378-392.	0.9	16
321	Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease. PLoS ONE, 2020, 15, e0227077.	1.1	7
322	Brain pathology and cerebellar purkinje cell loss in a mouse model of chronic neuronopathic Gaucher disease. Progress in Neurobiology, 2021, 197, 101939.	2.8	6
323	Diseases and conditions that impact maternal and fetal health and the potential for nanomedicine therapies. Advanced Drug Delivery Reviews, 2021, 170, 425-438.	6.6	16
324	The Role of iPSC Modeling Toward Projection of Autophagy Pathway in Disease Pathogenesis: Leader or Follower. Stem Cell Reviews and Reports, 2021, 17, 539-561.	1.7	5
325	Fronto-temporal dementia risk gene TMEM106B has opposing effects in different lysosomal storage disorders. Brain Communications, 2021, 3, fcaa200.	1.5	5
326	Brain Microglial Activation Increased in Glucocerebrosidase (<scp>GBA</scp>) Mutation Carriers without Parkinson's disease. Movement Disorders, 2021, 36, 774-779.	2.2	49
327	Genetic defects in the sphingolipid degradation pathway and their effects on microglia in neurodegenerative disease. Cellular Signalling, 2021, 78, 109879.	1.7	16
328	Lipids, lysosomes and mitochondria: insights into Lewy body formation from rare monogenic disorders. Acta Neuropathologica, 2021, 141, 511-526.	3.9	31
329	Alpha-Synucleinopathies. , 2021, , 387-410.		0
330	Gaucher disease: Basic and translational science needs for more complete therapy and management. Molecular Genetics and Metabolism, 2021, 132, 59-75.	0.5	28
331	Murine Models of Lysosomal Storage Diseases Exhibit Differences in Brain Protein Aggregation and Neuroinflammation. Biomedicines, 2021, 9, 446.	1.4	12
332	c-Abl activates RIPK3 signaling in Gaucher disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166089.	1.8	16
333	Impact of Gba2 on neuronopathic Gaucherâ€™s disease and Î±-synuclein accumulation in medaka (Oryzias) Tj ETQq1 1 0.784314 rgB	1.3	3
334	Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease. Frontiers in Neurology, 2021, 12, 636139.	1.1	26
335	Neurodegenerative Disease Risk in Carriers of Autosomal Recessive Disease. Frontiers in Neurology, 2021, 12, 679927.	1.1	6
336	Inhibition of Ceramide Synthesis Reduces Î±-Synuclein Proteinopathy in a Cellular Model of Parkinsonâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 6469.	1.8	17
337	Glucocerebrosidase dysfunction in neurodegenerative disease. Essays in Biochemistry, 2021, 65, 873-883.	2.1	4

#	Article	IF	Citations
338	Progress in generating iPSC-derived dopaminergic neurons as accurate models of neurodegenerative disease. , 2021, , 181-203.		0
339	Reduced cerebral vascularization in experimental neuronopathic Gaucher disease. Journal of Pathology, 2018, 244, 120-128.	2.1	17
340	Gangliosides and Glycolipids in Neurodegenerative Disorders. Advances in Neurobiology, 2014, 9, 449-461.	1.3	17
341	Apoptosis in Neurodegenerative Diseases. , 2009, , 479-504.		1
342	Lysosomal Storage Diseases. , 2012, , 403-451.		655
343	Substrate reduction therapy for lysosomal storage diseases. Acta Paediatrica, International Journal of Paediatrics, 2005, 94, 69-75.	0.7	37
344	mTOR hyperactivity mediates lysosomal dysfunction in Gaucher's disease iPSC-neuronal cells. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	44
345	The Saccadic and Neurological Deficits in Type 3 Gaucher Disease. PLoS ONE, 2011, 6, e22410.	1.1	62
346	Neuropathology in Mouse Models of Mucopolysaccharidosis Type I, IIIA and IIIB. PLoS ONE, 2012, 7, e35787.	1.1	148
347	Systemic Delivery of a Glucosylceramide Synthase Inhibitor Reduces CNS Substrates and Increases Lifespan in a Mouse Model of Type 2 Gaucher Disease. PLoS ONE, 2012, 7, e43310.	1.1	70
348	Properties of Neurons Derived from Induced Pluripotent Stem Cells of Gaucher Disease Type 2 Patient Fibroblasts: Potential Role in Neuropathology. PLoS ONE, 2015, 10, e0118771.	1.1	39
349	In-depth phenotyping for clinical stratification of Gaucher disease. Orphanet Journal of Rare Diseases, 2021, 16, 431.	1.2	11
351	The Genetics of Alzheimerâ€™s Disease and Parkinsonâ€™s Disease. Advances in Neurobiology, 2011, , 695-755.	1.3	7
352	Progressive myoclonic epilepsy and horizontal gaze palsy: a rare aetiology. BMJ Case Reports, 2017, 2017, bcr-2017-222304.	0.2	0
354	Alpha-Synucleinopathies. Advances in Medical Diagnosis, Treatment, and Care, 2019, , 274-297.	0.1	2
355	Parkinsonism and Related Disorders. , 0, , .		0
356	Psychosis in Gaucher's Disease. Psychiatric Annals, 2020, 50, 317-320.	0.1	0
358	Eye movement biomarkers allow for the definition of phenotypes in Gaucher Disease. Orphanet Journal of Rare Diseases, 2020, 15, 349.	1.2	6

#	Article	IF	Citations
359	Gaucher diseaseâ€"neuronopathic forms. , 2020, , 439-449.		0
360	The Lysosome and Nonmotor Symptoms: Linking Parkinson's Disease and Lysosomal Storage Disorders. Movement Disorders, 2020, 35, 2150-2155.	2.2	5
361	Gaucher Disease: New Expanded Classification Emphasizing Neurological Features. Iranian Journal of Child Neurology, 2019, 13, 7-24.	0.2	6
362	Glycosphingolipids. Advances in Experimental Medicine and Biology, 2021, 1325, 61-102.	0.8	11
363	Neurocognitive profile of adults with the Norrbottnian type of Gaucher disease. JIMD Reports, 2022, 63, 93-100.	0.7	2
364	LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease. Translational Neurodegeneration, 2022, 11, 5.	3.6	21
365	Gaucher disease â€“ more than just a rare lipid storage disease. Journal of Molecular Medicine, 2022, 100, 499-518.	1.7	13
366	Neuroinflammation in Gaucher disease, neuronal ceroid lipofuscinosis, and commonalities with Parkinsonâ€™s disease. Brain Research, 2022, 1780, 147798.	1.1	8
367	Pathological Î±-syn aggregation is mediated by glycosphingolipid chain length and the physiological state of Î±-syn inÂvivo. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	19
368	Delineating the Neuropathology of Lysosomal Storage Diseases Using Patient-Derived Induced Pluripotent Stem Cells. Stem Cells and Development, 2022, 31, 221-238.	1.1	2
369	Genetics of Non-Motor Symptoms of Parkinsonâ€™s Disease. , 2022, , 199-211.		0
370	Implications of Sphingolipids on Aging and Age-Related Diseases. Frontiers in Aging, 2022, 2, .	1.2	7
371	GBA Variants and Parkinson Disease: Mechanisms and Treatments. Cells, 2022, 11, 1261.	1.8	61
372	The role of lysosomal cathepsins in neurodegeneration: Mechanistic insights, diagnostic potential and therapeutic approaches. Biochimica Et Biophysica Acta - Molecular Cell Research, 2022, 1869, 119243.	1.9	26
373	Synucleinopathies. , 2014, , 149-175.		0
375	Can We Treat Neurodegenerative Proteinopathies by Enhancing Protein Degradation?. Movement Disorders, 2022, 37, 1346-1359.	2.2	11
377	Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism. International Journal of Molecular Sciences, 2022, 23, 5842.	1.8	8
378	Clinical Manifestations and Molecular Backgrounds of Parkinson's Disease Regarding Genes Identified From Familial and Population Studies. Frontiers in Neurology, 0, 13, .	1.1	6

#	Article	IF	Citations
379	Thirty-year clinical outcomes after haematopoietic stem cell transplantation in neuronopathic Gaucher disease. Orphanet Journal of Rare Diseases, 2022, 17, .	1.2	7
380	Epigallocatechin Gallate (<scp>EGCG</scp>) for Parkinson's Disease. Clinical and Experimental Pharmacology and Physiology, 0, , .	0.9	7
381	Neuronal activity induces glucosylceramide that is secreted via exosomes for lysosomal degradation in glia. Science Advances, 2022, 8, .	4.7	21
382	Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy. ELife, 0, 11, .	2.8	11
383	Glucocerebrosidase mutations and Parkinson disease. Journal of Neural Transmission, 2022, 129, 1105-1117.	1.4	19
385	Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease. Frontiers in Neurology, 0, 13, .	1.1	7
386	Neuronopathic Gaucher disease: Beyond lysosomal dysfunction. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	6
387	A multifaceted evaluation of microgliosis and differential cellular dysregulation of mammalian target of rapamycin signaling in neuronopathic Gaucher disease. Frontiers in Molecular Neuroscience, 0, 15, .	1.4	4
388	GBA1 and The Immune System: A Potential Role in Parkinsonâ€™s Disease?. Journal of Parkinson's Disease, 2022, 12, S53-S64.	1.5	3
389	Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial. Brain, 2023, 146, 461-474.	3.7	8
390	Targeting the Complementâ€“Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy. International Journal of Molecular Sciences, 2022, 23, 14340.	1.8	7
391	From Lysosomal Storage Disorders to Parkinsonâ€™s Disease â€“ Challenges and Opportunities. Journal of Molecular Biology, 2023, 435, 167932.	2.0	3
392	Exploring therapeutic strategies for infantile neuronal axonal dystrophy (INAD/PARK14). ELife, 0, 12, .	2.8	5
393	The Biology of Lysosomes: From Order to Disorder. Biomedicines, 2023, 11, 213.	1.4	4
394	Direct activation of microglia by Î²-glucosylceramide causes phagocytosis of neurons that exacerbates Gaucher disease. Immunity, 2023, 56, 307-319.e8.	6.6	11
395	a-Synuclein and lipids in erythrocytes of Gaucher disease carriers and patients before and after enzyme replacement therapy. PLoS ONE, 2023, 18, e0277602.	1.1	1
396	Exploring Pro-Inflammatory Immunological Mediators: Unraveling the Mechanisms of Neuroinflammation in Lysosomal Storage Diseases. Biomedicines, 2023, 11, 1067.	1.4	5
397	The ovine Type II Gaucher disease model recapitulates aspects of human brain disease.. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2023, 1869, 166658.	1.8	1

#	Article	IF	Citations
398	Genetic Evidence for Endolysosomal Dysfunction in Parkinsonâ€™s Disease: A Critical Overview. International Journal of Molecular Sciences, 2023, 24, 6338.	1.8	2
399	Other diseases of the CNS. , 2023, , 629-672.		0